Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001054953 | SCV001219314 | pathogenic | Ellis-van Creveld syndrome; Curry-Hall syndrome | 2024-11-11 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg911*) in the EVC gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in EVC are known to be pathogenic (PMID: 23220543). This variant is present in population databases (rs767400887, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with EVC-related conditions. ClinVar contains an entry for this variant (Variation ID: 850722). For these reasons, this variant has been classified as Pathogenic. |
Genomic Research Center, |
RCV001169863 | SCV001251771 | pathogenic | not provided | 2020-05-03 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV001169863 | SCV002024518 | likely pathogenic | not provided | 2022-08-24 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV001054953 | SCV002812013 | likely pathogenic | Ellis-van Creveld syndrome; Curry-Hall syndrome | 2023-12-29 | criteria provided, single submitter | clinical testing | |
Genomic Medicine Center of Excellence, |
RCV001729784 | SCV005438482 | pathogenic | Ellis-van Creveld syndrome | 2024-12-18 | criteria provided, single submitter | clinical testing | |
Center for Molecular Medicine, |
RCV001729784 | SCV001977076 | pathogenic | Ellis-van Creveld syndrome | 2021-10-05 | no assertion criteria provided | clinical testing | |
Natera, |
RCV001729784 | SCV002083061 | pathogenic | Ellis-van Creveld syndrome | 2021-08-04 | no assertion criteria provided | clinical testing |